Engineered immune cells take on tough blood cancers
NCT ID NCT04684563
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 22 times
Summary
This early-phase trial tests a new treatment called huCART19-IL18 for people with certain blood cancers (leukemia and lymphoma) that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified to better find and attack cancer cells. The main goals are to check safety, find the best dose, and see if the cells can be made reliably for each patient.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.